Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy

Head and Neck

Volumn 32, Issue 7, 2010, Pages 829-836

  Bhatia, Aarti ^a   Rao, Archana ^a   Ang, Kie Kian ^a   Garden, Adam S ^a   Morrison, William H ^a   Rosenthal, David I ^a   Evans, Douglas B ^a   Clayman, Gary ^a   Sherman, Steven I ^a   Schwartz, David L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anaplastic; Conformal; IMRT; Radiotherapy; Thyroid cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTARABINE; DOXORUBICIN; FLUDARABINE; PACLITAXEL;

ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; CONTINUOUS INFUSION; DEHYDRATION; DISTANT METASTASIS; ESOPHAGUS STRICTURE; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; IRRADIATION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RADIOSENSITIZATION; THYROID CANCER; THYROID GLAND; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANAPLASIA; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 77954417182     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21257     Document Type: Article

References (23)

1. Kitamura Y, Shimizu K, Nagahama M, et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 1999;84:4043-4049. (Pubitemid 30644192)
2. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453-464.
3. Simpson WJ. Anaplastic thyroid carcinoma: a new approach. Can J Surg 1980;23:25-27. (Pubitemid 10159897)
4. Pasieka JL. Anaplastic thyroid cancer. Curr Opin Oncol 2003;15:78-83.
5. De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:1137-1143.
6. Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 2002;86:1848-1853.
7. Junor EJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 1992;18:83-88.
8. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987;60:2372-2375.
9. Haigh PI, Ituarte PH, Wu HS, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001;91:2335-2342.
10. Sugino K, Ito K, Mimura T, et al. The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 2002;131:245-248.
11. Brignardello E, Gallo M, Baldi I, et al. Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur J Endocrinol 2007;156:425-430.
12. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990;66:321-330.
13. Nilsson O, Lindeberg J, Zedenius J, et al. Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg 1998;22:725-730.
14. Tan RK, Finley RK III, Driscoll D, Bakamjian V, Hicks WL III, Shedd DP. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 1995;17:41-48.
15. Wong CS, Van Dyk J, Simpson WJ. Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 1991;20:3-9.
16. Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 1999;16:64-69.
17. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130:1028-1034. (Pubitemid 34014569)
18. Besic N, Auersperg M, Us-Krasovec M, Golouh R, Frkovic-Grazio S, Vodnik A. Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol 2001;27:260-264.
19. Kobayashi T, Asakawa H, Umeshita K, et al. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck 1996;18:36-41. (Pubitemid 26002035)
20. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-4713.
21. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-4719.
22. Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Curr Opin Oncol 2008;20:19-24.
23. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-3416.